Biogen Inc. (NASDAQ: BIIB) has steadily declined since peaking at $468.55 in 2021, as shares are trading down 70.64% from those highs to 12-year lows at $137.33. The medical sector biotechnology ...

Biogen's Q4 2024 earnings showed slight revenue growth but Wall Street remains unimpressed due to weak guidance and declining key drug franchises. Leqembi's commercial performance is disappointing ...

Providing a diverse range of perspectives from bullish to bearish, 10 analysts have published ratings on Biogen (NASDAQ:BIIB) in the last three months. The following table summarizes their recent ...

Revenue: US$9.68b (down 1.6% from FY 2023). Net income: US$1.63b (up 41% from FY 2023). Profit margin: 17% (up from 12% in FY 2023). The increase in margin was driven by lower expenses. EPS: US$11 ...

Today, a brief rundown of news involving Neumora Therapeutics and Pliant Therapeutics, as well as updates from Biogen, AbbVie and SpringWorks Therapeutics that you might have missed. Garuda ...

My name is Jennifer and I will be your conference operator today. At this time, I'd like to welcome everyone to the Biogen Fourth Quarter and Full Year 2024 Earnings Call and Business Update.

For 2025 as compared to 2024, Biogen (BIIB) expects operating margin percentage to remain relatively flat. The Fit for Growth program is expected to generate approximately $1B of gross savings and ...

Forecasts 2025 profit below expectations Signs $250 million deal for lupus drug funding Shares drop more than 6% in early trading Feb 12 (Reuters) - Biogen (BIIB.O), opens new tab on Wednesday ...

Biogen Idec Inc. (BIIB) and Biovitrum AB (BIOVY, BVT.SK) said they will move ahead in testing their protein treatment for a type of hemophilia after it was well tolerated in an earlier study. The ...